2026年开年,中国创新药对外BD交易势头不减,再攀新高。医药魔方NextPharma数据库显示,截至2月15日(中国春节假期期间暂未新增交易事件),中国创新药已发生39起license-out交易事件,首付款约29.53亿美元,总金额超490亿美元。这意味着,开年45天,中国创新药对外BD交易首付款规模已超过2025年任一季度,总金额更已超过2025年全年水平的1/3。2021年至2026年截至...
Source Link2026年开年,中国创新药对外BD交易势头不减,再攀新高。医药魔方NextPharma数据库显示,截至2月15日(中国春节假期期间暂未新增交易事件),中国创新药已发生39起license-out交易事件,首付款约29.53亿美元,总金额超490亿美元。这意味着,开年45天,中国创新药对外BD交易首付款规模已超过2025年任一季度,总金额更已超过2025年全年水平的1/3。2021年至2026年截至...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.